Undisclosed Clin1 C. difficile colitis; undisclosed Clin0 COVID-19; undisclosed Clin0 IBD; undisclosed Clin0 cardiometabolic disease
Lumen Bioscience is developing new drugs for highly prevalent diseases. Many highly prevalent diseases have proven impossible to treat with traditional drug-making tools, despite much research. Lumen is using their unique technology to address these issues. Using their patented technology, Lumen is developing biologic drugs faster and with lower cost and risk than traditional methods. This involves the innovative use of spirulina cells to generate the therapeutic protein - these cells require only water, salt, CO2 and light making production cheap and rapidly scalable. As a platform company, Lumen can create their own portfolio of commercially viable therapies.
QC Specialist, Biochemical Assays
Seattle, WA|8 days ago